1 IGRAs in Children Deborah Anne Lewinsohn, MD Associate Professor Infectious Disease, Pediatrics
2 Disclosure Statement: Deborah Lewinsohn I have no significant financial interests in Cellestis or Oxford Immunotech. All relevant financial interests are as follows: Cellestis: Honoraria for three Cellestis-sponsored meetings for role as a participant, moderator, or invited speaker. Oxford Immunotech: Sponsored research contract to provide T cells to use for QC for T-spot.TB.
3 Natural History of M. tuberculosis Infection 1 Progressive Disease (<5% vs %) Bacterial Load Reactivation Disease (5-10%) Persistent Infection (90% vs 5-50%) Innate (TST-) Acute Adaptive (TST+) Chronic Adapted from: Henry Boom, TBRU, CWRU
4 Diagnosis of LTBI using TST Photographs: Dr. Chuck Daley, National Jewish Medical Center Problems include: Inter-reader variability; requires return visit. Confusing cutoffs for various risk groups. Low positive predictive value in countries with low prevalence False negatives Anergy: HIV/ESRD Recent TB Very young Overwhelming disease False positives BCG vaccination Nontuberculous mycobacteria
5 Diagnosis of Mtb infection by TST: TB controllers comfort food
6 T cell based diagnostics for TB: IFN-γ Release Assays (IGRA s) Potent pro-inflammatory cytokine released by T cells and NK cells. Assays reflect adaptive T cell response to TB. Two commercially available tests: T-spot.TB; ELISPOT. QuantiFERON -TB Gold IT; ELISA.
7 Antigens Absent from BCG ESAT-6
8 TST vs IGRA
10 QuantiFERON-TB PPD vs. QuantiFERON-TB Gold Antigen QFT-TB PPD (1 st ) QFT-TB Gold (2 nd ) PPD ESAT-6 M. Avium control CFP10 Mitogen Control Mitogen
11 QuantiFERON -TB Gold IT: ELISA 1 ml 1 ml 1 ml Transport Nil TB Antigens CFP-10 ESAT-6 TB7.7 Mitogen < 16 hours at Incubation at 37º room temperature Adapted from QuantiFERON -TB Gold IT product insert
12 QuantiFERON -TB Gold IT: ELISA Interpretation of test result Antigen From: QuantiFERON -TB Gold IT product insert
13 T-spot.TB: ELISPOT CPT tubes ELISPOT assay Transport < 8 hr at room temperature From: T-spot.TB Visual procedure guide
14 T-spot.TB: ELISPOT Interpretation of test result The test result is Positive if (Panel A-Nil) and/or (Panel B-Nil) 8 spots. The test result is Negative if both (Panel A-Nil) and (Panel B-Nil) 4 spots. The test result is Borderline if the highest of the Panel A or Panel B spot count (minus Nil) is 5, 6 or 7. The test result is Invalid if: Nil > 10 spots. Mitogen < 20 spots AND both (Panel A-Nil0 and (Panel B-Nil) 4 spots. From: Summarized from T-spot.TB Product insert
15 Use of IGRA s in adults CDC Recommendations: QFT-G can be used in all circumstances in which the TST is used, including contact investigations, evaluation of recent immigrants who have had BCG vaccination, and TB screening of health-care workers and others undergoing serial investigation for Mycobacterium tuberculosis infection. QFT-G usually can be used in place of (and not in addition to the TST) (MMWR, Dec. 16, 2005, Vol.54.) FDA Approvals: QFT TB (11/28/01); QFT TB Gold (12/2/04); QFT TB Gold-IT (10/10/07) T-SPOT.TB (7/25/08)
16 Evidence-based evaluation of IGRA s vs TST Evaluation without reference to a gold standard diagnostic for LTBI: Sensitivity in culture positive TB. Relationship with exposure risk factors. Specificity in low risk populations. Prospective prognostic studies.
17 Evaluation vs TST in children: Promise of IGRA s Evaluation without reference to a gold standard diagnostic for LTBI: Sensitivity in culture positive TB. Relationship with exposure risk factors. Specificity in low risk populations. Prospective prognostic studies.
18 QFT-Gold for Diagnosis of LTBI in active TB QFT version Study, year, country QFT Gold Connell, 2006, Australia QFT Gold Okada, 2007, Cambodia QFT Gold IT Connell, 2008, Australia QFT Gold IT Detjen, 2007, Germany QFT Gold IT Dogra, 2007, India QFT Gold IT QFT Gold IT Dominguez, 2007, Spain Kampmann, 2009, UK Age range Young/total Sensitivity of TST in active TB n/n (%) Sensitivity of IGRA in active TB n/n (%) 0-18 NR/101 9/9 (100) 9/9 (100) /210 < 6 yrs 15/19 (79) 10/19 (53) 1-19 NR/100 NR 8/9 (89) % < 3 yrs; n = /105 (40%) < 5 yrs /134 (11%) < 5 yrs /91 < 5 years 28 /28 (100) 26/28 (93) 5/8 (52) Cx+ 9/11 (82)-Rx 5/8 (52) Cx+ 9/11 (82) -Rx 9/9 (100) 6/9 (67) 20/24 (83) Cx+ 20/25 (80) Cx+
19 T-spot.TB for Diagnosis of LTBI in active Study, year, country Connell, 2008, Australia Detjen, 2007, Germany Dominguez, 2007, Spain Kampmann, 2009, UK Nicol, 2009, S. Africa Warier, 2009 India TB Age range Young/total Sensitivity of TST in active TB n/n (%) Sensitivity of IGRA in active TB n/n (%) 1-19 NR/101 NR 9/9 (89) % < 3 yrs; n = /134 (11%) < 5 yrs /91 < 5 years 0 -NR 204/214 < 3 years 28 /28 (100) 26/28 (93) 9/9 (100) 6/9 (67) 20/24 (83) 14/24 (58) 30/58 (52) 23/58 (40) 0-18 NR/15 NR 8/15 (53) Cx+
20 Evaluation vs TST in children: Promise of IGRA s Evaluation without reference to a gold standard diagnostic for LTBI: Sensitivity in culture positive TB. Relationship with exposure risk factors. Specificity in low risk populations. Prospective prognostic studies.
21 QFT-Gold for LTBI diagnosis QFT version Study, year, country Age range Young/total TST positivity rate n/n (%) Concordance TST/IGRA QFT Gold Connell, 2006, Australia 0-18 NR/101 42/42 (100) 11/42 (26); K = 0.30; TST+/QFT- QFT Gold Hesseling, 2008, S. Africa /29 15/28 (54) NR (88.9); K = 0.78; TST+/QFT- QFT Gold Mandalakas, 2008, S. Africa NR, X = 4.4 All HIV+; NR/23 6/23 (26) NR (75) K =.44; TST+/QFT- QFT Gold Okada, 2007, Cambodia /210 : < 6 yrs 47/195 (24) 171/195 (88); K = 0.62; TST+/QFT- QFT Gold IT Chun, 2008, Korea 0-13 NR: Med = 1.7 yr 26/42 (62) 24/42 (57); K = 0.19 QFT Gold IT Connell, 2008, Australia 1-19 NR/100 47/97 (48) NR; (75); K =.5 QFT Gold IT Lighter, 2008, USA /207, < 5 yrs 116/204 (56) 112/207 (55); K =.17 TST+/QFT- QFT Gold IT Nakaoka,2006, Nigeria 0-14 NR/207 57/206 (28) 49/66 (74); K =.74; TST-/QFT+ QFT Gold IT Dogra, 2007, India /105, < 5 yrs 10/105 (9.5) 100/105; (95); K =.73 QFT Gold IT Dominguez, 2007, Spain /134 (11%) 115/134 (86) BCG-:23/40 (58), K=.24 QFT Gold IT Kampmann,2009, UK /118; < 5 yrs 57/114 (50) NR (77); K =.53 QFT Gold IT Tsiouris, 2006, South Africa 5-15 NA/NR 80/184 (44) 145/184 (79); K=.56; TST+/QFT-
23 T-spot.TB for LTBI diagnosis Study, year, country Connell, 2008, Australia Dominguez, 2007, Spain Hesseling, 2008, South Africa Kampmann, 2009, UK Age range Young/total TST positivity rate n/n (%) Concordance TST/QFT 1-19 NR/100 47/97 (48) 75% K = /134 (11%) 115/134 (86) BCG-:25/40 (62), K= /29 15/28 (54) NR (46), K=-0.15 TST-/IGRA /118; < 5 yrs 57/114 (50) NR (75); K =.49 Mandalakas, 2008, S. Africa NR, X = 4.4 All HIV+; NR/23 6/23 (26) NR (67) K =.33; TST-/IGRA+
24 Evaluation vs TST in children: Promise of IGRA s Evaluation without reference to a gold standard diagnostic for LTBI: Sensitivity in culture positive TB. Relationship with exposure risk factors. Specificity in low risk populations. Prospective prognostic studies.
25 Specificity of Diagnosis of LTBI in TB suspects: QFT-IT/ T-spot.TB vs TST FT-TB Gold-IT vs T-spot, Germany PD Chiron (10 TU), positive 5 mm Detjen, et al., CID, 2007.
26 Specificity of Diagnosis of LTBI in TB suspects: QFT-IT/ T-spot.TB vs TST FT-TB Gold-IT vs T-spot, Germany PD Chiron (10 TU), positive 5 mm Detjen, et al., CID, 2007.
27 Specificity of IGRA in BCG-vaccinated children Inclusion: No risk and TST 5 mm. 62 children age 2 months 14 years, all BCG vaccinated. 0/62 QFT-IT positive FT-IT, Korea PD RT 23 ( 2 TU), positive 5 mm induration Chun, et al., Diag Micro Inf Dis, 2008
28 Evaluation vs TST in children: Promise of IGRA s Evaluation without reference to a gold standard diagnostic for LTBI: Sensitivity in culture positive TB. Relationship with exposure risk factors. Specificity in low risk populations. Prospective prognostic studies.
29 Diagnosis of LTBI/school contacts: QFT y/o boys, all BCG vaccinated. Tested with TST: 95 of 349 positive. 88 TST positive tested with QFT-TB Gold: 4 of 88 positive. 3 of 4 in high exposure group received INH. Remaining TST positive students no INH and no disease with 3+ years follow-up. FT-TB Gold, Japan PD Nippon ( 2.5 TU), positive 30 mm erythema Higuchi, K., et al., Respirology, 2007
30 Limitations of IGRA s in Children Paucity of data in children < 5 years. Increased frequency of indeterminate assays in children < 5 years. Required blood volumes. Lack of longitudinal data.
31 Limitations of IGRA s in young children QFT version Study, year, country Age range Young/total Indeterminate n/n (%) QNS Blood n/n (%) QFT Gold Connell, 2006, Australia 0-18 NR/101 17/101 (17) 3/101 (3) QFT Gold Hesseling, 2008, S. Africa /29 3/21 (14) 7/29 (24) QFT Gold Mandalakas, 2008, S. Africa NR, X = 4.4 All HIV+; NR/23 0/12 (0) 11/23 (47) QFT Gold Okada, 2007, Cambodia /210 : < 6 yrs 9/208 (6) 13/217 (6) QFT Gold IT Bruzzese, 2009, Italy 2-24 NR; all HIV neg, 16/80 (20) NR immunocomp QFT Gold IT Chun, 2008, Korea 0-13 NR: Med = 1.7 yr 17/227 (7.5) NR QFT Gold IT Connell, 2008, Australia 1-19 NR/100 0/38 (0) 5/101 (5) QFT Gold IT Lighter, 2008, USA /207, < 5 yrs 3/207 (1) 0/207 (0) QFT Gold IT Nakaoka,2006, Nigeria 0-14 NR/207 33/207 (16) NR QFT Gold IT Dogra, 2007, India /105, < 5 yrs 0/105 (0) 0/105 (0) QFT Gold IT Dominguez, 2007, Spain /134 (11%) 3/134 (2) NR QFT Gold IT Kampmann,2009, UK /118; < 5 yrs 14/209 (7) 0/209 (0) QFT Gold IT Tsiouris, 2006, South Africa 5-15 NA/NR NR 37/221 (17)
32 Indeterminate rates of IGRA s Black bars = < 4 years. White bars = 4 years FT-TB Gold vs QFT-IT vs T-spot, taly Bergamini, et al., Pediatrics, 2009.
33 Longitudinal IGRA data in children FT-IT rance Herrmann et al., PLoS ONE, 2009.
34 Longitudinal IGRA data in children FT-IT rance Herrmann et al., PLoS ONE, 2009.
35 QFT vs T-SPOT.TB Specificity: QFT BCG-vaccinees Sensitivity: T-SPOT.TB Immunocompromised Young children
36 What would we like in a test? Specificity and Sensitivity: The DiCaprinator With permission: Photoshop by David Lewinsohn
37 QFT vs T-SPOT.TB in children QFT more available than T-SPOT.TB More published data in children for QFT than for T-SPOT.TB. Less indeterminate results for T-SPOT.TB compared to QFT. Less blood required for T-SPOT.TB than for QFT. Specificity equivalent in one study. Sensitivity of T-SPOT.TB increased, equal, decreased when compared with QFT-IT. Increase positive tests with T-SPOT.TB
38 Indications for IGRA s and TST in children (My opinion) Close contacts of active TB cases: Immigrants from endemic countries: Significant travel history: IGRA preferred to TST in children 5 years. TST preferred to IGRA in children < 5 years.
39 Indications for IGRA s and TST in children (My opinion - continued) TB suspects: HIV infection: Increased risk of progression of LTBI: Consider both IGRA and TST and take either positive as evidence of infection.
40 Upcoming recommendations ATS/CDC/IDSA (AAP) guidelines: CDC guidelines updated for QFT-Gold-IT and T-SPOT.TB. AAP 2009 RedBook
41 Future research needs for IGRA s in children High risk young children in low incidence setting (Household contact study in young children). Longitudinal data in young children (Data to inform window prophylaxis ). Young immunosuppressed and HIVinfected children.
42 New assays for TB diagnosis in children IP-10 assays (ELISA/CD4) IFN-γ, IL-2, TNF-α (Flow cytometry) CD8+ T cells (ELISPOT) Antibodies in lymphocyte supernatant (ALS)
43 Slides Credits: Henry Boom Chuck Daley David Lewinsohn Madhu Pai
Interferon Gamma Release Assays (IGRAs) Lisa Y. Armitige, MD, PhD May 13, 2015 TB for Pulmonologist Phoenix, AZ March 13, 2015 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following
What is an IGRA? Are they available here? How do I use them? Debbie Staley, RN, MPH TB Nurse Consultant VDH Division of Disease Prevention TB Control Program Learning Objectives Participants will be able
Guidelines for TB Blood Testing Minnesota Department of Health TB Prevention and Control Program June 2011 Outline Interferon-Gamma Release Assays aka TB blood tests 1. What are they? 2. What are the current
IGRA Use in a Local Public Health Setting LAURIE HICKSTEIN, RN, BSN SENIOR PUBLIC HEALTH NURSE HALEY BLAKE DISEASE INVESTIGATION AND INTERVENTION SPECIALIST Disclaimer We have done no research for companies
Pocket Guide QuantiFERON -TB Gold CDC TB Testing Guidelines and Recent Literature Update Using IGRAs for TB screening in your patients June 2010 A full copy of the US Centers for Disease Control and Prevention
Interferon Gamma Release Assays(IGRAs): Yesterday, Today and Tomorrow Grand Rounds Philip LoBue, MD, FACP, FCCP Associate Director for Science Division of Tuberculosis Elimination National Center for HIV/AIDS,
Recommendations and Reports January 31, 2003 / 52(RR02);15-18 Guidelines for Using the QuantiFERON -TB Test for Diagnosing Latent Mycobacterium tuberculosis Infection Prepared by Gerald H. Mazurek, M.D.
PERFORMANCE OF QUANTIFERON TB GOLD IN-TUBE IN SERIAL TESTING OF LATENT TUBERCULOSIS INFECTION AMONG HEALTH CARE WORKERS RAFIZA SHAHARUDIN (IMR) KG RAMPAL (PERDANA UNIVERSITY) INTRODUCTION Health care workers
IGRA guidelines P. Van Bleyenbergh and Respiratory Infections Working Group Financial statement The speaker has no financial involvement with any organization or entity with a financial interest in the
Interferon Gamma Release Assays (IGRAs) in the Diagnosis of Tuberculosis Richard B. Clark, PhD, D(ABMM) Quest Diagnostics Nichols Institute Chantilly, VA Dale Schwab, PhD, D(ABMM) Quest Diagnostics Nichols
Nevada State Health Division Technical Bulletin Topic: Using QuantiFERON and Tuberculin Skin Test to Screen for TB Section/Program/Contact: Bureau of Community Health / Tuberculosis Program / Susanne Paulson,
Med. J. Cairo Univ., Vol. 79, No. 1, June 169-175, 2011 www.medicaljournalofcairouniversity.com Role of Quantiferon-TB Gold Assays in Detecting Latent Tuberculous Infection among Contacts of Active Tuberculous
Diagnosis of Latent TB Infection Douglas B. Hornick, MD Pulmonologist w/ Infectious Attitude Division of Pulm/Crit Care/Occ Med UI Carver College of Medicine 2014 MFMER slide-1 Disclosures: None 2014 MFMER
Morbidity and Mortality Weekly Report www.cdc.gov/mmwr Recommendations and Reports June 25, 2010 / Vol. 59 / No. RR-5 Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium
Interferon-gamma Release Assays: the Good, the Bad, and the Ugly Susan E. Dorman, MD Center for TB Research Johns Hopkins University School of Medicine Maryland Center for Tuberculosis Control and Prevention
Health Protection Agency position statement on the use of Interferon Gamma Release Assay (IGRA) tests for Tuberculosis (TB) Draft Interim HPA Guidance HPA Tuberculosis Programme Board Health Protection
Serial Testing for TB Infection with IGRAs: Understanding the Sources of Variability Niaz Banaei MD Assistant Professor of Pathology and Medicine Director, Fellowship in Global Health Diagnostics Director,
Interpretation of IGRA Results A View from the Clinical Lab Aker/Zvonkovic Photography Edward A. Graviss, PhD, MPH email@example.com TMH Clinical Lab CLIA certified 2006 (BCM) - QFT 2008 (TMH) - QFT and
TB diagnostics in western and poor countries suggestions for progress George Janossy (Royal Free, emeritus professor) in collaboration with Drs. Marc Lipman, Simon Barry, Ronan Breen, Tim McHugh et al.
Frequently Asked Questions QuantiFERON -TB Gold Health Professionals www.quantiferon.com 2 FAQ - Health Professionals Table of contents About TB 6 What is latent TB? And how is it different from active
Massachusetts Department of Public Health Division of Global Populations and Infectious Disease Prevention Screening Infants and Children for Tuberculosis in Massachusetts Executive Summary In Massachusetts,
New Ways to Detect TB all about Interferon Gamma Release Assays (IGRAs) Scott Stienecker MD FACP FSHEA Medical Director for Epidemiology and Infection Prevention Parkview Health Office 266-1170, Cell 260-438-1426
Distribution Agreement In presenting this thesis or dissertation as a partial fulfillment of the requirements for an advanced degree from Emory University, I hereby grant to Emory University and its agents
IGRAs: What do they tell and what don t they tell us? 2 nd European Advanced Clinical Tuberculosis Course Monday 22 nd September 2014 Amsterdam, Netherlands Ibrahim Abubakar Professor of Infectious Disease
Frequently Asked Questions A child has history of BCG vaccination, should they have TST or IGRA? According to the American Academy of Pediatrics Red Book (2012), Interferon Gamma Release Assay (IGRA) is
San Francisco Guidelines on the Use of QuantiFERON-TB Gold (In Tube Method) for the Diagnosis of Latent TB Infection Rationale When to Screen for TB Choosing the Right TB Test Patient Registration Pre-Test
Screen for TB with confidence QuantiFERON -TB Gold Plus the most accurate test for TB infection Sample to Insight TB is a preventable disease Tuberculosis (TB) is a contagious and deadly disease that is
Tuberculosis Exposures at Santa Clara Valley Medical Center May 11, 2016 Objectives To provide basic definitions of tuberculosis including differentiation between active tuberculosis disease and latent
ORIGINAL STUDIES The Likelihood of an Indeterminate Test Result from a Whole-Blood Interferon- Release Assay for the Diagnosis of Mycobacterium tuberculosis Infection in Children Correlates With Age and
QuantiFERON-TB Gold Validation at the San Diego County Public Health Laboratory Aline Grigorian, PhD San Diego County Public Health Laboratory August 13, 2008 SDPHL Serology QuantiFERON-TB (QFT) Testing:
2 COMPARISON OF MANTOUX AND QUANTIFERON-TB GOLD TEST FOR DIAGNOSIS OF LATENT TUBERCULOSIS INFECTION IN ARMY PERSONNEL Willeke P.J. Franken 1, Joost F. Timmermans 2, Corine Prins 1, Evert-Jan H.J. Slootman
Testing for Latent TB Infection: Recent Advances and Implications for Occupational Health Edward A. Nardell, MD Chief, Pulmonary Medicine The Cambridge Hospital Associate Professor, HMS, HSPH Director,
REVIEW CME CREDIT EDUCATIONAL OBJECTIVE: Readers will use and interpret the new blood tests for tuberculosis correctly CYNDEE MIRANDA, MD Department of Infectious Disease, Medicine Institute, Cleveland
QuantiFERON TB Gold In Tube Method (QGIT Test) Manufacturer: Cellestis Inc. (USA) a QIAGEN Company P1078 TB APPRISE TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed
Review For reprint orders, please contact firstname.lastname@example.org Diagnosis of latent Mycobacterium tuberculosis infection: is the demise of the Mantoux test imminent? James S Rothel and Peter Andersen
Journal of Infectious Diseases Advance Access published January 26, 2015 1 Effect of immune status on serial QuantiFERON-TB Gold In-Tube LTBI screening in persons with HIV in a low TB incidence country
Use of QuantiFERON TB Gold In Tube for TB Surveillance May 8, 2013 Landa A. PoianiDarocki RN, MSN, APN BC, COHN S, FAAOHN L. PoianiDarocki, Meridian Health 2013 1 Learning Objectives Describe Interferon
Chapter 3 Testing for Tuberculosis Infection and Disease Table of Contents Chapter Objectives.... 45 Introduction.... 47 Identifying High-Risk Groups for M. tuberculosis Testing... 47 Testing Methods for
TUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY Stephanie N. Lin MD 2/12/2016 Epidemiology of TB 9.6 million new cases in 2014 12% of them are in HIV positive patients 1.5 million deaths in 2014 ~646
Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial update) Short clinical guideline Draft for consultation, July 2010 This short clinical guideline was developed following
What You Need to Know About Collecting QuantiFERON (QFT) TB Gold In-Tube Samples I. What is QuantiFERON (QFT) TB Gold In-Tube? II. III. QFT is an interferon-gamma release assay (IGRA). QFT is a blood test.
An Evaluation of QuantiFERON-TB Gold In-Tube and Immunological Tests for TB Diagnosis in Iraqi Patients Mohemid M. Al-Jebouri 1 and Nuha M. Wahid 2 1 Department of Microbiology, College of Medicine, University
Targeted Testing and Treatment of Latent TB Infection L. Masae Kawamura, M.D. Director, TB Control Section San Francisco Department of Public Health Francis J. Curry National TB Center University of California,
Maria Dalbey RN. BSN, MA, MBA March 17 th, 2015 2 Objectives Participants will be able to : Understand the Pathogenesis of Tuberculosis (TB) Identify the Goals of Public Health for TB Identify Hierarchy
Morbidity and Mortality Weekly Report Recommendations and Reports December 16, 2005 / Vol. 54 / No. RR-15 Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis Recommendations
Risk for Tuberculosis in Swiss Hospitals 17. Tuberkulose Symposium Münchenwiler Risk for Tuberculosis in Swiss Hospitals Dr. med. Alexander Turk Zürcher Höhenklinik Wald email@example.com 1 Content
The old and the new: Immune-based diagnosis of childhood tuberculosis Shaun K. Morris, MD, MPH, FRCPC, The Hospital for Sick Children, Toronto Anne-Marie Demers, MD, FRCPC, CHU Sainte-Justine, Montréal
British Journal of Medicine & Medical Research 4(13): 2546-2554, 214 SCIENCEDOMAIN international www.sciencedomain.org An Evaluation of QuantiFERON-TB Gold in- Tube and Immunological Tests for TB Diagnosis
Am. J. Trop. Med. Hyg., 80(4), 2009, pp. 628 633 Copyright 2009 by The American Society of Tropical Medicine and Hygiene Serial Testing of Refugees for Latent Tuberculosis Using the QuantiFERON-Gold In-Tube:
Challenges in Pediatric Tuberculosis Mimi Emig, MD Spectrum Health Kent County Health Department Pediatric Tuberculosis: A Missed Public Health Opportunity Mimi Emig, MD Spectrum Health Kent County Health
A Three-Way Comparison of Tuberculin Skin Testing, QuantiFERON-TB Gold and T-SPOT.TB in Children Tom G. Connell 1,2,3., Nicole Ritz 1,2,3., Georgia A. Paxton 4, Jim P. Buttery 1,2,3, Nigel Curtis 1,2,3
Tuberculosis (TB) Screening Guidelines for Substance Use Disorder Treatment Programs in California 1 of 7 Table of Contents Preface 2 TB Symptoms and TB History 2 Initial Screening 2 Follow-Up Screening
CDPH - CTCA Joint Guidelines Guidelines for Prevention and Control of Tuberculosis In California Long Term Health Care Facilities Table of Contents Introduction. 3 1 Overview of Tuberculosis.. 3 1.1 Transmission
Clinical Review Clinical experience with QuantiFERON - TB Gold HIV/AIDS This clinical guide was reviewed and edited by: Michael Sension, MD Medical Director, HIV Clinical Research Broward Health Fort Lauderdale,
Recent Advances in The Treatment of Mycobacterium Tuberculosis Dr Mohd Arif Mohd Zim Senior Lecturer & Respiratory Physician Faculty of Medicine, Universiti Teknologi MARA firstname.lastname@example.org
QUANTIFERON -TB GOLD HEALTH TECHNOLOGY ASSESSMENT SECTION MEDICAL DEVELOPMENT DIVISION MINISTRY OF HEALTH i MALAYSIA 13/2013 DISCLAIMER Technology review is a brief report, prepared on an urgent basis,
Frequently Asked Questions QuantiFERON-TB Gold Health Professionals www.quantiferon.com Table of contents About TB 4 What is latent TB? And how is it different to active TB disease? 4 What is the meaning
Cost Comparison and Clinical Evaluation of a Blood Test for Tuberculosis (TB) in a Correctional Setting Princess Adaku Iroh, M.Sc. Academic and Health Policy Conference on Correctional Health March 20th,
Guidelines for Tuberculosis Screening of Healthcare Students in the greater Auckland region Auckland Regional Public Health Service 2013 Document Controller: Updated December 2013 Medical Officer of Health,
Perils and Pitfalls in Clinical Trials of Diagnostic Tests for Tuberculosis Richard O Brien, MD Foundation for Innovative New Diagnostics Geneva 1 Outline of Presentation Statement of the problem Common
TB Diagnostics: looking back and looking forward Raul V. Destura MD Institute of Molecular Biology and Biotechnology National Institutes of Health University of the Philippines, Manila Disturbing Statistics
TUBERCULOSIS AT A GLANCE A Reference for Practitioners on Basic Tuberculosis Information SECOND EDITION EXCELLENCE EXPERTISE INNOVATION December 2010 Dear Medical Practitioner and Health Care Worker, This
Comparison of Quantiferon-TB Gold versus Tuberculin Skin Test for Tuberculosis Screening in Inflammatory Bowel Disease Patients Gianluca Andrisani, Alessandro Armuzzi, Alfredo Papa, Manuela Marzo, Carla
Opportunistic Infections Related to Immune Suppressant and Biologic Drug Therapy in IBD Raymond Cross, M.D., M.S., AGAF Associate Professor of Medicine Director of the Inflammatory Bowel Disease Program
(In-Tube Method) The Whole Blood IFN-gamma Test Measuring Responses to ESAT-6, CFP-10 & TB7.7 Peptide Antigens PACKAGE INSERT For In Vitro Diagnostic Use BlanK Page INDEX 1. INTENDED USE 2 2. SUMMARY AND
Evaluation and Management of Pediatric Patients in Contact Investigations Andrea T. Cruz, MD, MPH Assistant Professor of Objectives Evaluation of the preschool-aged child exposed to tuberculosis Role of
Immunology Platform 2012 The scientific activity report of Immunology Platform of the Institut Pasteur du Cambodge for the period January 1st to December 31st, 2012. Scientific activity report Prepared
University of Bergen Comparison of Tuberculin Skin Test and QuantiFERON TB Gold In-tube Assay for the diagnosis of tuberculosis infection and disease in young children; study conducted as part of the development
Montana DPHHS Tuberculosis Program Assisted Living - TB Risk Assessment Assisted Living, Adult Day Care, Adult Foster Care & Transitional Living Centers Today s Date Facility Address Phone County Completed
Test Menu Infectious Diseases Laboratory Division of Infectious Diseases Department of Medicine March 2015 1 Atypical Pneumonia PCR Panel (APP)* The APP is an in-house developed, real-time (RT) PCR assay,
The Tuberculin Skin Test versus QuantiFERON TB GoldH in Predicting Tuberculosis Disease in an Adolescent Cohort Study in South Africa Hassan Mahomed 1,2 *, Tony Hawkridge 4, Suzanne Verver 5, Deborah Abrahams
Canadian Tuberculosis Standards 7 th Edition Chapter 4: Diagnosis of Latent Tuberculosis Infection Canadian Tuberculosis Standards, 7 th Edition is available on Internet at the following address: www.phac-aspc.gc.ca
ORIGINAL ARTICLE Tanaffos (2010) 9(3), 22-27 2010 NRITLD, National Research Institute of Tuberculosis and Lung Disease, Iran Role of QuantiFERON-TB Test in Detection of Children Infected with Mycobacterium
PACKAGE INSERT For In Vitro Diagnostic Use Only This package insert covers use of: T-SPOT.TB 8 (Multi-use 8-Well Strip Plate Format. Catalogue number: TB.300) T-SPOT.TB 50 (1200 test Multi-use version.
TB Intensive San Antonio, Texas November 11 14, 2014 TB in the HIV Patient Lisa Armitige, MD, PhD November 13, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests
QuantiFERON -TB Gold Plus (QFT -Plus) ELISA Package Insert The whole blood IFN-γ test measuring responses to ESAT-6 and CFP-10 peptide antigens For in vitro diagnostic use 2 x 96 622120 QIAGEN GmbH QIAGEN
Screening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults) H S Schaaf Department of Paediatrics and Child Health, and Desmond Tutu TB Centre Stellenbosch University, and Tygerberg
Subject Instructions for the screening of clients to detect tuberculosis (TB) in the context of the Canadian immigration medical examination (IME). Goal/Objective These instructions are provided to ensure
Tuberculosis in Children and Adolescents Ritu Banerjee, MD, Ph.D TB Clinical Intensive April 8, 2015 2014 MFMER slide-1 Disclosures None 2014 MFMER slide-2 Objectives Describe the epidemiology of pediatric
Tuberculosis Transmission in Households and Communities Christopher C. Whalen, M.D., M.S. Department of Epidemiology and Biostatistics 2008, The University of Georgia. All rights reserved. Model for M.
Regulations for Tuberculosis Control in Minnesota Health Care Settings A guide for implementing tuberculosis (TB) infection control regulations in your facility Tuberculosis Prevention and Control Program